CDC13 Antibody

What is CDC13 and why are antibodies against it important in research?

CDC13 is a specialized telomeric protein that plays essential roles in maintaining genome stability through chromosome end protection and telomere length regulation in yeast. It forms part of the Cdc13-Stn1-Ten1 (CST) complex that binds to single-stranded telomeric DNA. Antibodies against CDC13 allow researchers to detect protein levels, study protein-protein interactions, investigate post-translational modifications (particularly phosphorylation), and examine CDC13 localization at telomeres.

Research has demonstrated that CDC13 functions in telomere length regulation independently of its roles in chromosome end protection and telomerase recruitment . Using appropriate antibodies, researchers can distinguish between these distinct functions and track CDC13 behavior under various experimental conditions.

What types of CDC13 antibodies are most commonly used in telomere research?

Several types of CDC13 antibodies are employed in research settings:

• Tag-specific antibodies: Many studies use epitope-tagged versions of CDC13 (such as Myc-tagged CDC13) with corresponding anti-tag antibodies. CDC13 has been chromosomally tagged with Myc9 and detected using commercial anti-Myc antibodies from Roche .

• Direct anti-CDC13 antibodies: These are raised against purified CDC13 protein or synthetic peptides corresponding to CDC13 sequences.

• Phospho-specific antibodies: These recognize specific phosphorylated residues on CDC13, such as the Cdk1-dependent phosphorylation sites at T308 and S336 .

The choice depends on the specific research question, with tagged versions often preferred for high specificity when genetic modification is feasible.

What are the standard protocols for immunoprecipitating CDC13?

Based on published research, the standard immunoprecipitation protocol for CDC13 involves:

• Cell extract preparation (typically using TCA precipitation)

• Determining protein concentration and using a volume containing 20μg of protein

• Adding 1μl of anti-Myc antibody (for Myc-tagged CDC13)

• Incubating for 1 hour at 4°C

• Adding 20μl of protein A sepharose or protein G agarose slurry

• Extending incubation overnight at 4°C

• Washing extensively with lysis buffer

• Resuspending beads in SDS-PAGE sample buffer

• Incubating at 65°C for 20 minutes to elute proteins

• Analyzing by SDS-PAGE and western blotting

This protocol has been successfully used to study CDC13 interactions with other proteins and to analyze CDC13 modifications.

How are CDC13 antibodies used to detect phosphorylation states?

CDC13 undergoes important phosphorylation events that regulate its function. To detect these modifications:

• Phos-tag™ SDS-PAGE: This specialized technique incorporates acrylamide-pendant Phos-tag™ (10μM) into SDS-PAGE gels to retard the migration of phosphorylated proteins. Research shows this method has effectively resolved different phosphorylation states of CDC13 .

• Western blotting: After separation, standard western blotting with anti-CDC13 or anti-tag antibodies can detect mobility shifts caused by phosphorylation.

• Phospho-site mutant analysis: Comparing wild-type CDC13 with phosphorylation site mutants (e.g., cdc13-T308A, cdc13-S336A) helps identify specific phosphorylation events .

Research has demonstrated that CDC13 is phosphorylated by Cdk1 at T308 and S336 in the telomerase recruitment domain, and these modifications are critical for telomere maintenance .

What cell synchronization methods work best for CDC13 antibody experiments?

Cell synchronization is crucial for CDC13 studies since its expression and modifications vary throughout the cell cycle. Effective synchronization methods include:

• Nocodazole arrest: For G2/M synchronization. Research shows cdc28-4 cells were arrested with nocodazole at 23°C and then shifted to 37°C for 3 hours to study Cdk1-dependent phosphorylation .

• Temperature-shift with cell cycle mutants:

  • cdc10-129: For G1 arrest when shifted to 36°C

  • cdc28-4: For G1 arrest when shifted to 37°C

• Chemical inhibitors: 1-NMPP1 at 0.5mM has been used to inhibit cdc28-as1 (analog-sensitive) kinase .

• Flow cytometry verification: Cell synchronization is typically verified using propidium iodide staining and flow cytometry analysis .

These techniques allow researchers to study CDC13 at specific cell cycle stages, revealing regulatory mechanisms such as cell cycle-dependent phosphorylation.

How can CDC13 antibodies be used to study the telomerase recruitment process?

CDC13 antibodies are valuable tools for dissecting telomerase recruitment mechanisms:

• Domain-specific interaction studies: The telomerase recruitment domain of CDC13 (amino acids 252-491) has been identified using antibodies and fusion proteins . Phosphorylation sites T308 and S336 within this domain are crucial for telomerase recruitment.

• Co-immunoprecipitation: CDC13 antibodies can co-precipitate telomerase components like EST1. Researchers have created CDC13-EST1 fusion constructs to study their functional relationship .

• Mutant analysis: Comparing wild-type CDC13 with recruitment-defective mutants (e.g., cdc13-4) and phosphorylation site mutants (T308A, S336A) reveals factors affecting telomerase recruitment .

• Cell cycle studies: Synchronizing cells at different stages helps determine when recruitment occurs and correlates CDC13 phosphorylation state with recruitment efficiency.

These approaches have shown that CDC13's role in telomere length regulation can be separated from its functions in chromosome protection and telomerase recruitment .

What are the technical challenges in detecting CDC13-protein interactions?

When studying CDC13 interactions with other proteins, researchers face several technical challenges:

• Epitope tag interference: Tags may affect protein-protein interactions. Research shows successful use of Myc13-tagged CDC13 for co-immunoprecipitation experiments .

• Extraction conditions: Telomeric complexes are sensitive to extraction conditions. Harsh detergents may disrupt weaker interactions.

• Transient interactions: Some CDC13 interactions may be transient or cell cycle-dependent. In vivo cross-linking with formaldehyde can capture these interactions.

• Specificity verification: Confirming specific interactions requires:

  • Reciprocal co-IPs (immunoprecipitate with antibodies against both proteins)

  • Competition assays with purified domains

  • Comparison of wild-type and interaction-defective mutants

• Quantification: Accurate quantification requires appropriate imaging systems, such as the bioluminescence imaging system used in published research .

Addressing these challenges requires careful optimization of experimental conditions and rigorous controls.

How do phosphorylation events affect CDC13 antibody recognition?

CDC13 phosphorylation can significantly impact antibody recognition:

• Epitope masking: Phosphorylation can alter protein conformation, potentially masking antibody epitopes. This is particularly relevant for antibodies targeting regions near phosphorylation sites T308 and S336 .

• Mobility shifts: Phosphorylated CDC13 shows altered mobility on SDS-PAGE, especially when using Phos-tag™ technology. These shifts can affect the interpretation of western blot results .

• Antibody specificity: Some antibodies may have differential affinity for phosphorylated versus non-phosphorylated forms of CDC13.

• Cell cycle variations: CDC13 phosphorylation states change throughout the cell cycle, with hyperphosphorylated forms predominating in G2/M phase .

To address these issues, researchers should:

• Use phosphorylation-insensitive antibodies (targeting regions away from known phosphorylation sites)

• Include phosphatase-treated controls

• Compare results with phosphorylation site mutants (T308A, S336A)

• Consider using phospho-specific antibodies for specific applications

Research has demonstrated that Cdk1-dependent phosphorylation of CDC13 is critical for maintaining optimal function and expression levels .

What are the best strategies for validating CDC13 antibody specificity in mutant strains?

When working with CDC13 mutants, validating antibody specificity is crucial:

• Genetic controls:

  • Use CDC13 deletion strains (cdc13Δ::kanMX4, cdc13Δ::URA3) as negative controls

  • Include heterozygous strains (CDC13/cdc13Δ::kanMX4) for intermediate expression

  • Use isogenic wild-type strains as positive controls

• Epitope verification:

  • Confirm that mutations don't affect antibody binding sites

  • For point mutations (cdc13-4, cdc13-T308A), verify epitope preservation

• Expression normalization:

  • Use GAL1 promoter constructs (HIS3MX6-GAL1-HA3::CDC13) to achieve comparable expression of wild-type and mutant proteins

  • Quantify mRNA levels to ensure similar transcription

• Complementary detection:

  • Compare results with different antibodies targeting distinct epitopes

  • For tagged mutants, use both anti-tag and direct CDC13 antibodies

The research literature includes numerous CDC13 mutant strains that provide excellent controls for antibody validation, including phosphorylation site mutants and telomere length regulation mutants .

How can CDC13 antibodies be used to study CDC13 turnover and stability?

CDC13 protein levels are tightly regulated throughout the cell cycle. To study CDC13 turnover:

• Cycloheximide chase assays:

  • Treat cells with cycloheximide to inhibit protein synthesis

  • Collect samples at intervals and perform western blotting with CDC13 antibodies

  • Quantify protein levels to determine half-life

• Pulse-chase experiments:

  • Label proteins with [35S]methionine (as shown in studies measuring p56cdc13 translation rates)

  • Immunoprecipitate CDC13 at various time points

  • Quantify radioactivity to determine degradation rate

• Ubiquitination analysis:

  • Immunoprecipitate CDC13 and probe for ubiquitin

  • Compare ubiquitination patterns in wild-type and mutant strains

• Phosphorylation effects:

  • Compare stability of wild-type CDC13 with phosphorylation site mutants

  • Research shows Cdk1 phosphorylates CDC13, preserving optimal expression levels

• Cell cycle analysis:

  • Synchronize cells and collect samples throughout the cell cycle

  • Quantify CDC13 levels to determine cell cycle-dependent regulation

These approaches have revealed that CDC13 stability is regulated by phosphorylation and that proper turnover is essential for telomere length homeostasis .

What are the optimal conditions for CDC13 western blotting?

For optimal CDC13 western blotting results:

• Protein extraction:

  • TCA precipitation has proven effective for CDC13 extraction

  • Include protease inhibitors to prevent degradation

  • For phosphorylation studies, add phosphatase inhibitors

• Gel conditions:

  • For standard detection: 8-10% SDS-PAGE

  • For phosphorylation analysis: SDS-PAGE containing 10μM acrylamide-pendant Phos-tag™

• Transfer parameters:

  • Semi-dry transfer at 15V for 30-45 minutes

  • Wet transfer at 100V for 1 hour in cold room

• Blocking:

  • 5% non-fat milk in TBST for standard detection

  • 3-5% BSA in TBST for phosphorylation studies

• Antibody incubation:

  • Primary: Anti-Myc for Myc-tagged CDC13, 1:1000 dilution, overnight at 4°C

  • Secondary: HRP-conjugated anti-mouse, 1:5000, 1 hour at room temperature

• Detection:

  • Enhanced chemiluminescence

  • Bioluminescence imaging system for quantification

These conditions have been successfully used to detect CDC13 and its phosphorylated forms in various experimental contexts.

How should researchers troubleshoot weak or non-specific CDC13 antibody signals?

When facing weak or non-specific CDC13 antibody signals:

• For weak signals:

  • Increase protein loading (30-50μg per lane)

  • Optimize antibody concentration (perform titration)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use more sensitive detection methods (enhanced ECL substrates)

  • Consider protein enrichment by immunoprecipitation before western blotting

• For non-specific signals:

  • Increase blocking concentration (5-10% milk or BSA)

  • Add 0.1-0.5% Tween-20 to reduce background

  • Pre-absorb antibody with extracts from CDC13 deletion strains

  • Increase washing stringency (higher salt concentration, more wash steps)

  • Use monoclonal antibodies instead of polyclonal if available

• For high background:

  • Decrease secondary antibody concentration

  • Ensure complete removal of SDS from gels before transfer

  • Clean equipment thoroughly to remove residual proteins

• For inconsistent results:

  • Standardize protein extraction method

  • Include positive controls (known CDC13-expressing samples)

  • Use fresh reagents, especially detection substrates

These troubleshooting steps can significantly improve the quality of CDC13 antibody experiments.

What controls are essential for CDC13 immunoprecipitation experiments?

For rigorous CDC13 immunoprecipitation experiments, include these essential controls:

• Input control:

  • Save 5-10% of pre-IP lysate to confirm target protein presence

  • Compare with IP efficiency to assess percent recovery

• Negative controls:

  • No-antibody control (beads only)

  • Isotype-matched irrelevant antibody

  • Pre-immune serum for polyclonal antibodies

  • Extracts from CDC13 deletion strains when possible

• Specificity controls:

  • Competing peptide control (pre-incubate antibody with epitope peptide)

  • Comparison of wild-type and mutant strains

  • Pre-clearing of lysates to reduce non-specific binding

• Technical controls:

  • IgG heavy/light chain controls to distinguish from target protein

  • Clean test tubes to prevent contamination

  • Complete sample denaturation before SDS-PAGE

• Validation controls:

  • Reciprocal IP (if studying interactions)

  • Alternative antibodies targeting different epitopes

  • Mass spectrometry confirmation of immunoprecipitated proteins

The research literature demonstrates successful CDC13 immunoprecipitation using these controls, particularly in studies of protein-protein interactions and phosphorylation states .

How can researchers analyze contradictory results with different CDC13 antibodies?

When different CDC13 antibodies yield contradictory results:

• Epitope mapping:

  • Determine the exact epitopes recognized by each antibody

  • Check if epitopes lie in regions affected by mutations or post-translational modifications

  • Consider whether conformational changes might affect epitope accessibility

• Antibody validation:

  • Test antibodies on known positive and negative controls

  • Perform peptide competition assays to confirm specificity

  • Validate with genetic knockouts or knockdowns

• Technical differences:

  • Compare extraction methods, as some may preserve certain epitopes better

  • Test different fixation/denaturation conditions

  • Optimize blocking agents for each antibody

• Biological interpretation:

  • Different antibodies may detect different CDC13 subpopulations

  • Some may preferentially recognize specific post-translational modifications

  • Apparent contradictions may reveal biological complexity

• Cross-validation approaches:

  • Use complementary techniques (e.g., mass spectrometry)

  • Apply genetic approaches (e.g., epitope tagging)

  • Consult published literature for similar discrepancies

By systematically analyzing the source of contradictions, researchers can gain deeper insights into CDC13 biology rather than simply discarding "inconsistent" results.

What is the relationship between CDC13 phosphorylation and telomere maintenance?

Research using CDC13 antibodies has revealed critical relationships between CDC13 phosphorylation and telomere maintenance:

• Cell cycle-regulated phosphorylation:

  • CDC13 undergoes cell cycle-dependent phosphorylation, with hyperphosphorylated forms predominating in G2/M phase

  • This timing coincides with telomerase activity at telomeres

• Cdk1-dependent phosphorylation:

  • Cdk1 directly phosphorylates CDC13 at T308 and S336 within the telomerase recruitment domain

  • These phosphorylation events are essential for optimal CDC13 function and expression

• Telomerase recruitment:

  • Phosphorylated CDC13 more efficiently recruits telomerase components

  • Phosphorylation site mutants (T308A, S336A) show reduced telomerase recruitment

• Protein stability:

  • CDC13 phosphorylation affects protein turnover

  • Proper CDC13 turnover is essential for telomere length homeostasis

• Multiple regulatory pathways:

  • Besides Cdk1, other kinases like Tel1/Mec1 also phosphorylate CDC13

  • These pathways provide additional regulatory control over telomere maintenance

This research demonstrates that CDC13 phosphorylation serves as a critical regulatory mechanism linking cell cycle progression to telomere maintenance activities.

How should researchers interpret CDC13 expression patterns across different mutant strains?

When analyzing CDC13 expression across different mutant strains:

• Expression level variations:

  • Distinguish between transcriptional and post-transcriptional effects

  • Consider protein stability differences between mutants

  • Verify that tagging doesn't differentially affect expression

• Post-translational modification patterns:

  • Examine phosphorylation states using Phos-tag™ gels

  • Compare hyperphosphorylated vs. hypophosphorylated forms

  • Correlate modification patterns with functional outcomes

• Subcellular localization:

  • Determine if mutations affect nuclear localization or telomere binding

  • Consider if altered localization explains functional differences

• Genetic background effects:

  • Account for strain background variations

  • Include isogenic controls whenever possible

  • The research uses various W303 background strains with different CDC13 mutations

• Statistical analysis:

  • Perform multiple biological replicates (minimum three)

  • Conduct appropriate statistical tests to determine significance

  • Quantify band intensities using imaging systems

Careful interpretation of expression patterns can reveal important insights into CDC13 regulation and function, particularly when correlated with telomere phenotypes.

What CDC13 domains are most important for antibody development and research applications?

Understanding CDC13 domain structure is crucial for antibody development and application:

• DNA-binding domain (DBD):

  • Located in the C-terminal region

  • Highly conserved and structurally characterized

  • Good target for antibodies studying telomere binding functions

• Telomerase recruitment domain (RD):

  • Contains amino acids 252-491

  • Contains critical phosphorylation sites T308 and S336

  • Important target for studying telomerase recruitment mechanisms

• N-terminal domain:

  • Contains regulatory elements

  • Less well-characterized but functionally important

  • GST-CDC13(1-252) has been used in research

• C-terminal domain:

  • GST-CDC13(601-781) has been studied

  • Contains elements important for protein-protein interactions

When developing antibodies:

• Target conserved regions for cross-species applications

• Avoid highly disordered regions for better specificity

• Consider whether post-translational modifications might interfere with epitope recognition

• For phospho-specific antibodies, target known regulatory sites like T308 and S336

These domain-specific considerations help researchers select or develop antibodies appropriate for their specific research questions.

How can CDC13 antibody data be integrated with genetic and functional studies?

For comprehensive understanding of CDC13 function, researchers should integrate antibody-based data with genetic and functional studies:

• Correlation with phenotypes:

  • Link protein levels/modifications to telomere length phenotypes

  • Compare antibody-detected changes with cellular phenotypes

  • Research demonstrates CDC13 functions independently in telomere length regulation and chromosome protection

• Structure-function relationships:

  • Use domain-specific antibodies to link structural features to functions

  • Compare wild-type and mutant proteins (e.g., cdc13-4)

  • Analyze how phosphorylation affects domain interactions

• Genetic interaction mapping:

  • Study CDC13 antibody detection in various genetic backgrounds

  • Research examines CDC13 in tel1Δ and est2Δ backgrounds

  • Determine whether certain mutations affect CDC13 levels or modifications

• Temporal dynamics:

  • Track CDC13 changes during cell cycle or in response to stress

  • Correlate with functional responses and genetic requirements

  • Cell synchronization experiments reveal cell cycle-dependent regulation

• Systems biology approaches:

  • Integrate antibody data with genomic, proteomic, and functional datasets

  • Build network models of CDC13 interactions and regulations

  • Identify novel regulatory mechanisms

This integrated approach provides deeper insights than any single method alone and helps resolve apparent contradictions between different experimental systems.